U.S. Stock Insider Trading | Sangamo Therapeutics disclosed 10 insider transactions on February 26

2026-03-26 21:30:20

On February 26, 2026, Sangamo Therapeutics (SGMO) disclosed 10 insider trades. Director Macrae Sandy sold 33,600 shares on February 25, 2026.

【Recent Insider Trades】

Disclosure Date	Position	Name	Trade Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 26, 2026	Executive	Dubois-Stringfellow Nathalie	February 25, 2026	Sell	12,400	0.47	5,806.38
February 26, 2026	Executive	Dubois-Stringfellow Nathalie	February 24, 2026	Sell	2,063	0.47	974.77
February 26, 2026	Executive	Jain Nikunj	February 25, 2026	Sell	5,119	0.47	2,405.93
February 26, 2026	Executive	Jain Nikunj	February 24, 2026	Sell	666	0.47	314.69
February 26, 2026	Director	Macrae Sandy	February 24, 2026	Sell	5,291	0.47	2,500.00
February 26, 2026	Director	Macrae Sandy	February 25, 2026	Sell	33,600	0.47	15,800.00
February 26, 2026	Executive	Davis Gregory D	February 25, 2026	Sell	5,119	0.47	2,405.93
February 26, 2026	Executive	Davis Gregory D	February 24, 2026	Sell	832	0.47	393.12
February 26, 2026	Executive	Willoughby Scott B.	February 24, 2026	Sell	1,650	0.47	779.63
February 26, 2026	Executive	Willoughby Scott B.	February 25, 2026	Sell	12,400	0.47	5,806.38

【Company Profile】

Sangamo Therapeutics, Inc. was incorporated on June 22, 1995, in Delaware. The company focuses on the development and commercialization of novel transcription factors for gene regulation and gene editing. It is a clinical-stage biopharmaceutical company dedicated to exploring new therapeutic strategies for unmet medical needs—specifically, research, development, and commercialization of DNA-binding proteins. Currently, the company’s scientific and business efforts are concentrated on gene regulation and editing using novel zinc finger DNA-binding protein engineering. The company’s strategy involves developing highly specific zinc finger nucleases and zinc finger transcription factors through early clinical trials and strategic partnerships with biopharmaceutical companies to conduct late-stage clinical trials and commercialization.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes